Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
- Author:
Sook Hee HONG
1
;
Yeon Sil KIM
;
Ji Eun LEE
;
In ho KIM
;
Seung Joon KIM
;
Daehee HAN
;
Ie Ryung YOO
;
Yang Guk CHUNG
;
Young Hoon KIM
;
Kyo Young LEE
;
Jin Hyoung KANG
Author Information
- Publication Type:Original Article
- Keywords: EGFR; Non-small cell lung carcinoma; EGFR tyrosine kinase inhibitor; Bone metastasis; Response Evaluation Criteria in Solid Tumors
- MeSH: Carcinoma, Non-Small-Cell Lung*; Disease Progression; Epidermal Growth Factor*; Humans; Lung Neoplasms; Neoplasm Metastasis*; Protein-Tyrosine Kinases; Receptor, Epidermal Growth Factor*; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Seoul
- From:Cancer Research and Treatment 2016;48(3):1110-1119
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this study was to analyze clinical characteristics of skeletal metastasis in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) and treatment outcomes of continued EGFR tyrosine kinase inhibitor (TKI) therapy in patients presenting with skeletal metastasis progression. MATERIALS AND METHODS: Of the 216 patients treated with EGFR-TKI for management of stage III-IV NSCLC between 2006 and 2012 in Seoul St. Mary's Hospital, 76 patients with confirmed EGFR-mutated NSCLC with skeletal metastases during therapy were analyzed retrospectively. RESULTS: Of 76 patients with EGFR mutant lung cancer with skeletal metastasis, 37 patients developed first progressive disease (PD) in skeletal regions. EGFR-TKI was continued in these 37 patients after first PD in skeletal regions. Median time to first PD of skeletal regions was 8.9 months (95% confidence interval [CI], 4.8 to 13.0). Median time of continued EGFR-TKI after first PD of skeletal regions was 8.0 months (95% CI, 2.9 to 13.0) in patients with disease progression of preexisting regions, 5.6 months (95% CI, 4.5 to 6.7) in patients showing new localized regions, and 3.3 months (95% CI, 1.1 to 5.5) in patients with multiple new metastatic regions (p=0.006). Median time of postskeletal metastasis progression survival was 23.0 months (95% CI, 13.5 to 32.5), 15.0 months (95% CI, 3 to 34.7), and 7.0 months (95% CI, 6.0 to 8.0) (p=0.004) in the above described patient groups, respectively. Overall, seven patients (18.9%) had more than one episode of skeletal progression of disease without extraskeletal PD. CONCLUSION: Continued EGFR-TKI treatment with adequate local treatment after progression of skeletal metastasis may be considered for patients who show disease progression in preexisting regions or local progression.
